Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Infectious Diseases

Open Access

Early serum screening for hepatocellular-carcinoma in patients with hepatitis

  • Alina Cristina Neguț1, 2Email author,
  • Anca Streinu-Cercel1, 2,
  • Oana Săndulescu1, 2,
  • Mădălina Carap3,
  • Mihaela Adriana Toderici3 and
  • Adrian Streinu-Cercel1, 2
BMC Infectious Diseases201414(Suppl 7):P28

https://doi.org/10.1186/1471-2334-14-S7-P28

Published: 15 October 2014

Background

Chronic hepatitis is an important problem worldwide, associating high morbidity and mortality, and hepatocellular-carcinoma is one of its most severe complications.

Multiple studies have tried to identify biomarkers that would allow an earlier detection of hepatocellular-carcinoma (HCC), compared to imagistic exams. Such biomarkers are represented by alpha-fetoprotein (AFP), des-γ-carboxy prothrombin (DPC), and the lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3).

Methods

Since January 2014, the National Institute for Infectious Diseases “Prof. Dr. Matei Balş” has implemented a screening program for hepatocellular carcinoma in patients with hepatitis. The program involves a serum panel performed in the Lotus-MED Medical Center, consisting of AFP, DCP and AFP-L3%, performed at two study visits: screening and 48 weeks follow-up. As the study is still ongoing, we present descriptive data derived from the first study visit.

Results

We have enrolled 120 patients; their mean age was 56.6±12.2 years, and the male-to-female ratio was 1.07:1. The patients were diagnosed with chronic hepatitis B (8.8%), chronic hepatitis C (72.5%), B+D coinfection (9.9%), idiopathic hepatitis (4.4%) and other causes of liver disease (4.4%). Only 65% of patients had cirrhosis, and 8% of them had a diagnosis of hepatocellular-carcinoma.

The mean values for the serum panel tests were 158.95±1419.82 ng/mL (AFP), 11.68±59.20 ng/mL (DCP), and 14.83±21.85% (AFP-L3%).

In the group of patients with cirrhosis, the positive prediction for HCC based on the serum panel tests was 32.20%. 23.53% of the persons with positive prediction already had a diagnosis of HCC, while 92.5% of the persons with negative prediction did not have a history of HCC. The test’s sensitivity for predicting HCC was 57.14%, and its specificity was 74%. The positive predictive value (PPV) was 23.53% and the negative predictive value (NPV) 92.5%.

Conclusion

Our preliminary results represent the first serum panel predictions for HCC in the population of Romanian patients with chronic hepatitis. However, given the fact that only 65% of patients displayed cirrhosis at the time of testing, the analysis has also been applied outside of its validated range, and we can only rely on the data available for patients with cirrhosis. The patients will be reinvestigated at 48 weeks, and only then will we be able to calculate an accurate sensitivity, specificity, PPV or NPV, as this serum test is thought to predict a patient’s probability of developing HCC over the next 6 months.

Declarations

Acknowledgements

1) POSDRU/159/1.5/S/141531 (Alina Cristina Neguț)

2) POSDRU/159/1.5/S/137390 (Anca Streinu-Cercel, Oana Săndulescu)

Authors’ Affiliations

(1)
Carol Davila University of Medicine and Pharmacy
(2)
National Institute for Infectious Diseases "Prof. Dr. Matei Balş"
(3)
Lotus-MED Medical Center

Copyright

© Neguț et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement